---
title: "Esophageal Cancer Cases"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
editor: visual
bibliography: zotero.bib
---


## Case 1

:::::: columns
:::: {.column width="50%"}
::: {style="font-size: 125%;"}
62M with longstanding reflux has first EGD.

Reflux got worse during training for a triathalon
:::
::::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}
![](https://deidt7p41jzcy.cloudfront.net/barretts_comm.png)
:::
::::
::::::



## Case 1

Pathology shows Barrett's metaplasia without dysplasia


:::::: columns
::: {.column width="50%"}
What is appropriate follow up?

Biopsy strategy?
:::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}

:::
::::
::::::



## Case 1 Barrett's metaplasia without dysplasia

:::::: columns
::: {.column width="50%"}
What is appropriate follow up?
:::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}
AGA Guidelines

- No dysplasia: 3-5 years
- Low grade dysplasia: 6-12 months
- High grade dysplasia 3 months
  - (in the absence of ablation)
:::
::::
::::::


## Case 1 Barrett's metaplasia without dysplasia


:::::: columns
::: {.column width="50%"}
Biopsy strategy?
:::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}
AGA Guidelines

- White light endoscopy
- 4-quadrant biopsy every 2cm
- Mucosal irregularity biopsied separately
- 4-quadrant biopsy every 1cm if dysplasia)

:::
::::
::::::



## Case 2

Pathology shows high-grade dysplasia


:::::: columns
::: {.column width="50%"}
Treatment Options:
:::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}

- [Observation]
- [Esophagectomy]
- [Cryotherapy]
- [Irreversible Electroporation]
- [Radio-frequency Ablation]


:::
::::
::::::


## Observation

:::{.fragment}
You receive a hand-written note from the family 
:::

:::{.fragment}
inviting you to the funeral of the patient 
:::

:::{.fragment}
who passed after a heroic battle with esophageal cancer
:::



[Case 2]


## Esophagectomy

Correct answer, wrong century (not the 20th)

[Case 2]

## Cryotherapy

Correct answer, wrong century (not the 22nd)

[Case 2]



## Irreversible Electroporation

![](https://www.mcgill.ca/oss/files/oss/styles/hd/public/frankenstein3.jpg)


[Case 2]

## Radio-frequency Ablation

::::: columns
::: {.column width="30%"}
Radiofrequency Ablation results in eradication of Barrett's in 75% at 1 year
:::

::: {.column width="70%"}
![](images/shaheen.png)
:::
:::::

::: aside
[@shaheen2277]
:::

[Case 3]

## Case 3

EGD shows a nodule in the Barrett's esophagus


:::::: columns
::: {.column width="50%"}
Treatment Options:
:::

:::: {.column width="50%"}
::: {.content-visible unless-format="docx"}

- [Surveillance]
- [Minimally Invasive Esophagectomy]
- [Endoscopic Mucosal Resection]
- [Radio-frequency Ablation Barxx]


:::
::::
::::::





## Surveillance

:::{.fragment}
You receive a hand-written note from the family 
:::

:::{.fragment}
inviting you the patient's 70th birthday 
:::

:::{.fragment}
after being treated at a competing medical center
:::

:::{.fragment}
for esophageal cancer
:::


[Case 3]


## Minimally Invasive Esophagectomy

Correct answer, wrong patient

[Case 3]

## Endoscopic Mucosal Resection

Endoscopic procedure resects mucosal tumor

![](https://deidt7p41jzcy.cloudfront.net/emr_comm.png)

[Case 4]

## Radio-frequency Ablation Barxx

Correct answer, wrong question



## Case 4

Your patient from Case 2 returns with dysphagia and weight loss


![](https://deidt7p41jzcy.cloudfront.net/eso_egd2.png)


## Case 4 Adenocarcinoma

Pathology shows adenocarcinoma

Workup?


## Case 4 Adenocarcinoma

Workup?

- [Barium Swallow]
- [Endoscopic Ultrasound]
- [CT Chest/Abdomen/Pelvis]

## Barium Swallow

Correct answer, wrong century

[Case 4]

## Endoscopic Ultrasound


:::{.fragment}
You receive a hand-written note from the family 
:::

:::{.fragment}
inviting you the patient's 70th birthday 
:::

:::{.fragment}
after they died from an esophageal perforation
:::

:::{.fragment}
which occured during EUS
:::

:::{.fragment}
Autopsy showed T3 adenocarcinoma
:::

[EUS in Patients with Dysphagia]


[Case 4]

## CT Chest/Abdomen/Pelvis

What test do you order next?

## PET scan

:::::: columns
::: {.column width="40%"}
A PET scan is most accurate method of staging esophageal cancer
:::

:::: {.column width="60%"}
::: {.content-visible unless-format="docx"}
![](https://deidt7p41jzcy.cloudfront.net/PetImage.png)
:::
::::
::::::

::: {.content-hidden unless-format="docx"}
In some cases, the PET scan is not performed until a CT scans bas been done.
:::


## T3 N0 M0 adenocarcinoma

Treatment Options - First Treatment Course

- [MI Esophagectomy]
- [Chemo + Radiation]
- [Chemotherapy]


## MI Esophagectomy

Correct answer, wrong timing

Why?

[T3 N0 M0 adenocarcinoma]


## Chemo + Radiation

Concurrent chemotherapy and radiation followed by surgery = Trimodality therapy

## CROSS Trial

-   368 esophageal cancer patients randomized:
    -   Surgery alone
    -   Chemo+RT $\rightarrow$ Surgery
-   75% adenocarcinoma
-   T3: 80%. T2: 17%
-   age $\tilde{x}$=60
-   longer survival with Chemo+RT $\rightarrow$ Surgery

CROSS Trial Details

Chemotherapy: Weekly carboplatin and paclitaxel Radiation: 4140 cGy in 23 fractions (180cGy/fraction)

::: aside
[@shapiro1090]
:::

## CROSS - Overall Survival

![Surgery vs ChemoRT $\rightarrow$ Surgery](images/shapiro_1090_fig2a.png){fig-align="left"}

::: aside
[@shapiro1090]
:::

## CROSS - Survival by Histology

![Surgery vs ChemoRT $\rightarrow$ Surgery](images/shapiro_1090_fig2b.png){fig-align="left"}

::: aside
[@shapiro1090]
:::

## CROSS - Adenocarcinooma

Median survival 43mo vs 27mo

Pathologic complete response in 23%

## CROSS - Squamous cell carcinoma

Median survival 82mo vs 21mo

Pathologic complete response in 40%

::: aside
[@shapiro1090]
:::

## T3 N0 M0 Adenocarcinoma

Family asks if there is a better treatment option than CROSS

## Chemotherapy

"Sandwich" Chemotherapy may be superior to Trimodality therapy

## EsoPEC Trial

-   Adenocarcinoma esophagus - T1 N+ or T2-4a M0. Median age =63. 89% men

-   Randomized to CROSS (n=217) vs FLOT chemotherapy (n=221) = 438

-   CROSS: carboplatin/paclitaxel + 4140cGy $\rightarrow$ Surgery

-   FLOT: FLOT $\rightarrow$ Surgery $\rightarrow$ FLOT

-   Excluded: Squamous cell, gastric cancer, T1N0, T4b, M1

## EsoPEC Trial Results

-   Surgery performed in 371/438 patients

-   90-day mortality 4.3% (3.2% in FLOT and 5.6% CROSS)

-   Median survival 66mo in FLOT arm and 37mo in Cross arm

-   3-year overall survival 57% FLOT vs 51% CROSS

-   5-year overall survival 51% FLOT vs 29% CROSS

-   pCR 17% for FLOT and 10% CROSS


## Case 7

Patient returns after FLOT chemotherapy

What are risks of surgery?


## Preoperative Evaluation

![](https://deidt7p41jzcy.cloudfront.net/eso_risk.png)

## Preoperative Evaluation

![](https://deidt7p41jzcy.cloudfront.net/eso_risk.png)

25th percentile: Grip Strength 26kg (men) / 16kg (women)



## Case 7

Patient returns after FLOT chemotherapy

What are surgical options?

## Low Risk Adenocarcinoma

![](https://deidt7p41jzcy.cloudfront.net/decision_low.png)


## High Risk Adenocarcinoma
![](https://deidt7p41jzcy.cloudfront.net/surg_high.png)


## Surgery for Esophageal Cancer

Surgery for esophageal cancer is performed for:

-   Superficial Tumors (T1) not completely removed by endoscopy
-   Localized Tumors (T2N0)
-   Locally Advanced (T3) after preoperative therapy.

## Goals of Surgery

::::: columns
::: {.column width="50%"}
-   Remove tumor from esophagus
-   Remove surrounding lymph nodes
-   Create a new esophagus
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_Resection1_ai.png)
:::
:::::

## Ivor Lewis (Transthoracic) Esophagectomy

::::: columns
::: {.column width="50%"}
-   Removes tumor
-   Removes lower 1/3 of esophagus
-   Removes surrounding lymph nodes
-   Reconstruction of GI tract
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_Resection2_ai.png)
:::
:::::

## Reconstruction

::::: columns
::: {.column width="50%"}
A new esophagus is created from the stomach in the abdomen by fashioning it into a tube.
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_Resection3_ai.png)
:::
:::::


## Minimally-invasive Ivor Lewis

::::: columns
::: {.column width="50%"}
-   Laparoscopic mobilization of stomach
-   Construction of gastric conduit
-   Thoracic anastomosis
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/MIE_IvorLewisArtboard.png)
:::
:::::


## Ivor Lewis esophagectomy

::::: columns
::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/C21-FF3.png)
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/C21-FF6.png)
:::
:::::




## Ivor Lewis esophagectomy

::::: columns
::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/C21-FF7.png)
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/C21-FF8.png)
:::
:::::




## Thoracic Circular Stapled Anastomosis {background-video="https://deidt7p41jzcy.cloudfront.net/eso_eea.mp4" background-video-loop="true" background-video-muted="true"}


## Open Ivor Lewis

::::: columns
::: {.column width="50%"}
We use the mininally-invasive approach in 95% of cases

In some cases, an open approach is still necessary.
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/IvorLewisArtboard.png)
:::
:::::

## Total Esophagectomy

::::: columns
::: {.column width="50%"}
For patients with tumors in the upper esophagus, we need to remove more of the esophagus

We need to remove the whole esophagus, including the portion in the neck
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_ProxTumorArtboard.png)
:::
:::::

## McKeown Esophagectomy

::::: columns
::: {.column width="50%"}
All of esophagus removed ![](https://deidt7p41jzcy.cloudfront.net/Eso_ResectionTotalArtboard.png)
:::

::: {.column width="50%"}
Connection made in the neck ![](https://deidt7p41jzcy.cloudfront.net/Eso_MIE_McKeownArtboard.png)
:::
:::::


## Transhiatal Esophagectomy

::::: columns
::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_ResectionTotalArtboard.png)
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/Eso_MIE_THE_ai.png)
:::
:::::




## Colon Interposition

::::: columns
::: {.column width="50%"}
If the stomach is not suitable to make a new esophagus, the colon can be used to replace the esophagus
:::

::: {.column width="50%"}
![](https://deidt7p41jzcy.cloudfront.net/colon-interposition2.jpg)
:::
:::::

## Colon Interposition

![](https://deidt7p41jzcy.cloudfront.net/colon_interposition_elseiver.jpg)



## Esophageal Cancer Treatment Categories

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Dyplasia]           |    Tis     | Radiofrequency Ablation    |
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| [Locally-advanced]   | T3 or N^+^ | Chemo or ChemoRT â†’ Surgery |
| [Metastatic]         |     M1     | Chemotherapy +/- Radiation |


## Dyplasia

Radiofrequency Ablation for Dysplasia

::::: columns
::: {.column width="60%"}
127 patients with dysplasia randomized:

-   Radio-frequency ablation
-   Sham ablation

Low-grade dysplasia in 64

High-grade dysplasia in 63
:::

::: {.column width="40%"}
![](images/rfa_esophagus.png) ![Barxx](images/barxx.png)
:::
:::::

::: aside
[@shaheen2277]
:::

## Radiofrequency Ablation for Dysplasia

::::: columns
::: {.column width="30%"}
Radiofrequency Ablation results in eradication of Barrett's in 75% at 1 year
:::

::: {.column width="70%"}
![](images/shaheen.png)
:::
:::::

::: aside
[@shaheen2277]
:::

## Superficial Tumors

Workup of nodular Barretts:

-   Endoscopic Ultrasound
-   Endoscopic Mucosal Resection
    -   Diagnostic (T staging)
    -   May be therapeutic for T1a tumors

## Endoscopic Musocal Resection

![](images/EMR.jpg){fig-align="right"}

## Localized Tumors

Patients staged as uT2 N0 are candidates for primary surgery. *However:*

-   EUS has a 25% rate of understaging uT2 N0 tumors
-   Understaged patients who undergo primary surgery would need chemo or chemoRT postop

## Small Tumors (minimal dysphagia)

-   EUS to distinguish T2 from T3 tumors
-   If uT2 N0 $\rightarrow$ CT chest/abdomen/pelvis $\rightarrow$ Esophagectomy
-   If uT3 or N1 $\rightarrow$ PET $\rightarrow$ neoadjuvant therapy

Patients with dysphagia almost always are T3 tumors (and don't need EUS)

## Symptomatic Tumors (Dysphagia)

Patients with dysphagia to solids or weight loss or tumor length \>3cm are unlikely to have T1-2 tumors and can be initially evaluated with [PET Scan]

-   Disease confined to the esophagus and regional nodes $\rightarrow$ [Locally-advanced]
-   Metastatic disease $\rightarrow$ [Metastatic]
-   N3 $\rightarrow$ induction chemotherapy followed by chemoradiation and surgical evaluation.

## EUS in Patients with Dysphagia

Memorial Sloan Kettering[^1] patients with esophageal cancer:

[^1]: @ripley226

-   61 with dysphagia, 54 (89%) were found on EUS to have uT3-4 tumors.
-   53 without dysphagia, 25 (47%) were uT1-2 $\rightarrow$ candidates for primary surgery.

EUS can be omitted for patients with dysphagia, but is useful in patients *without* dysphagia.

## PET Scan

PET has more specificity and sensitivity than CT in detecting regional lymph node and distal metastasis [^2]

[^2]: @block770

## Locally-advanced

For patients with locally-advanced esophageal cancer, improved survival with adjunctive therapy. There are two options:

-   ChemoRT $\rightarrow$ Surgery ([CROSS Trial])
-   Chemo $\rightarrow$ Surgery $\rightarrow$ Chemo ([EsoPEC Trial])

## Surgery for Squamous Cell Carcinoma

Squamous Cell Carcinoma of the esophagus

- responds well to chemo+RT
- more difficul to get a surgical margin on the airway
- additional benefit of surgery on top of chemoRT is uncertain


## FFCD 9102 2007 (Bedenne)

All patients received 4500cGy RT + 2 cycles of cisplatin + 5FU

Patients with a clinical response were randomized:

-   Surgery -\> 2 year survival 34% Median 17.7mo

-   3 cycles of chemo + 2000 cGy RT -\> 2 year survival 40% Median 19.3mo

*No difference in overall survival* 

## German Trial (Stahl)

4000 cGY RT + Chemo $\rightarrow$ Surgery. 64% 2-year PFS. Mortality 12.8%

6500cGy RT + Chemo:  41% 2-year PFS. Mortality 3.5%

*No difference in overall survival* 

## Metastatic

FOLFOX is first-line systemic therapy for metastatic GI cancers

-   Dose-limiting toxicity is frequently peripheral neuropathy

## Orientation Handbook

::::: columns
::: {.column width="30%"}

:::

::: {.column width="70%"}
![](https://deidt7p41jzcy.cloudfront.net/handbook_qr.png)
:::
:::::

::: aside

:::

## References
